Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor...
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United Kingdom Government will purchase an additional...
CytoReason, an Israeli company developing computational disease models for more efficient drug discovery and development, today announced a collaboration with German multinational science and...
